The Effect of Decongestive Lymphatic Therapy with Pneumatic Compression for Breast Cancer-related Lymphedema

Han-Ju Tsai\textsuperscript{1}  Hsiu-Chuan Hung\textsuperscript{1}  Jing-Lan Yang\textsuperscript{2}  
Chiun-Sheng Huang\textsuperscript{3}  Jau-Yih Tsauo\textsuperscript{1,4,*}

**Background and Purpose:** Many investigators measured treatment effectiveness of decongestive lymphatic therapy (DLT) combined with pneumatic compression (PC). However, most of them did not use controls. **Objectives:** This study aimed to investigate the effectiveness of this management using the subjects themselves as controls to minimize the influence of spontaneous change with time. **Methods:** Subjects with unilateral breast cancer-related lymphedema were recruited. Each subject went through a control period, an intervention period and three measurements. They were treated with DLT combined with 1-hour PC for 2 hours/session, one session/day, 5 sessions weekly for 4 weeks. The outcome measures included demographic and medical information, the severity of swelling, water composition, lymphedema-related symptoms, quality of life and subjects’ compliance. One-way repeated measures and Friedman tests were used to examine the differences among three evaluations. **Results:** There was no significant change in all of the measurements in the control period. Significant reductions in excess water displacement, excess circumference, excess water composition ($p<0.0083$) and 5 symptoms after intervention ($p<0.0167$). **Conclusions:** The use of DLT combined with PC in treating patients with lymphedema has shown positive therapeutic responses. (FJPT 2010;35(2):89-97)

**Key Words:** Breast cancer, Breast cancer-related lymphedema, Decongestive lymphatic therapy, Lymphedema, Pneumatic compression

Breast cancer-related lymphedema is a common complication occurs through the course of treatments for breast cancer. It is defined as arm edema in the breast cancer patient is caused by interruption of the axillary lymphatic system by surgery or...
radiation therapy, which results in the accumulation of fluid in subcutaneous tissue in the arm, with decreased distensibility of tissue around the joints and increased weight of the extremity. According to the survey of Motimer et al., fourth of breast cancer patients suffered from lymphedema, which causes physical, psychological, and functional impacts and increases the risk of repeated superficial infections.

Decongestive lymphatic therapy (DLT), is also known as complex decongestive therapy, complex lymphedema therapy, multimodel physical therapy, complex decongestive physiotherapy, and complete decongestive physical therapy. It is a comprehensive multidisciplinary lymphedema therapy, has been recommended as a primary treatment by consensus panels and is an effective therapy for lymphedema unresponsive to standard elastic compression therapy. It consists of skin care, manual lymphedema drainage (MLD), compression wrapping, exercises, and followed by maintenance program and psychosocial rehabilitation. Pneumatic compression (PC) is a mechanical method to deliver compression to the swollen limbs. It is often combined with DLT to treat patients with breast cancer-related lymphedema. Although the use of PC is extensive, the optimum parameters have not been determined. Some researchers do not support the use of PC because pressure greater than 50-60 mmHg might injure superficial lymphatic vessels. Other experts support the use of PC, generally suggesting the use of a lower pumping pressure (40 mmHg) as part of a comprehensive program. It concluded that when DLT is used adjunctively with pneumatic compression therapy, it enhanced the therapeutic response.

Many studies aimed at measuring effectiveness of DLT or combination of its subsets. Most studies were quasi-experimental designs without real control groups (no treatment at all) because once the lymphedema was established, the symptoms had an inexorable tendency to progress, and provision of treatment was necessary. Therefore, conducting a standardized, randomized controlled trial is difficult under ethical consideration. Erickson et al. pointed out that numerous studies focus on the efficacy of DLT, but all were cohort studies that evaluated patients before and after therapy. Only tentative conclusions should be drawn from these studies.

Therefore, we have modified the study design by using the subjects themselves as controls, and aim to investigate the effectiveness of DLT when combined with PC.

METHODS

Study Design

A prospective study design with a 4-week control period (the first month) followed by a 4-week intervention period (the second month) was administered. Subjects maintained ordinary management for their lymphedema throughout the whole study period. The ordinary management is defined as the management that subjects received and did concurrently in the hospital such as pneumatic compression and self management at home such as elevation or MLD. The study protocol was approved by the hospital ethics committee and all participants provided written consent.

Subjects

Subjects were referred from hospitals, foundations and associations from August 2004 to June 2005. These organizations are around the Taipei area and serve patients with breast cancer. Those who fulfilled the following criteria were eligible for the study: 1) unilateral breast cancer-related lymphedema for at least 3 months, 2) moderate to severe lymphedema (excess circumference of the affected limb larger than 2 cm at least on one measured site). The exclusion criteria were as follows: 1) active cancer or disease that might lead to swelling, or on diuretic therapy or other lymphedema-influencing drugs, 2) port-A catheter on chest wall of affected side with adhesion, 3) skin disease, 4) irremovable bracelet or ring on affected upper extremities, 5) the restriction of active range of motion in affected upper extremity was greater than half range.

Sample Size Estimation

Based on previous studies which had similar intervention, the effect sizes for limb volume reduction of these research were 0.46, 1.15, 1.20, the estimated sample size was 8, 8, and 39 respectively when setting a power of 80%, and an α of 5% was used to detect any difference between groups. The intervention in the current study was a combination of interventions of those studies. So we averaged the estimated sample size calculated from the data of these three studies. The average of the estimated sample size was 18.

Interventions

Each subject received DLT which consisted of 1) educa-
tion for skin care, 2) a 30-minute manual lymphatic drainage (MLD), 3) 1-hour of pneumatic compression therapy (at 40 mm Hg) (Lympha-Mat, German), 4) short-stretch bandage application (Rosidal® K, German), and, 5) 20-minute remedial exercises. Subjects were treated two hours per session, one session per day, five days weekly for 4 weeks (20 sessions of treatment in total).

MLD treatments were performed by four certified physical therapists (PT) following a procedure that drain the anterior trunk firstly, followed by drainage of the posterior trunk and affected arm. To make sure all the therapists offered similar massage pressure on patient, all the therapists experienced the massage pressure by setting a sphygmonanometer cuff on their own arms and practiced massage on their arms at the same time before commencement of this research. A gradient-sequential pneumatic pump (Lympha-Mat, German) with a twelve chambers sleeve was used for pneumatic compression therapy.

A short-stretch bandage was applied to the treated arm by the physical therapist after MLD and PC. The technique of applying the short-stretch bandage was also taught to the patients and/or their family in case they needed to re-apply it such as after bathing or intolerance of the pressure. We instructed all subjects to wear the bandage as long as possible.

After the bandage was applied, subjects then commenced exercises. The 20-minute exercise program included relaxation exercises, breathing exercises, and manual lymphatic drainage exercises. Patients were instructed to execute exercise at least twice per day at home.

**Outcome Measures**

All data were collected by one licensed PT. Three evaluations were carried out. The first was at the beginning of the control period. The second was at the transition between the control and intervention periods, and the third was at the end of the intervention period. Baseline and demographic data were recorded for each subject at the first evaluation, which included: 1) history of radiotherapy and chemotherapy, 2) surgery type, 3) number of excised lymph nodes, 4) post-operation duration, 5) time of lymphedema onset, 6) previous and concurrent treatment for lymphedema (Table 1.).

**Limb size**

Water-displacement volumetry and circumference measurement were used to quantify limb size. Water-displacement is a simple and direct method to measure the volume of ir-

<table>
<thead>
<tr>
<th>Items</th>
<th>Mean±SD [median]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>57.9±9.8</td>
</tr>
<tr>
<td>Body Mass Index</td>
<td>24.5±3.9</td>
</tr>
<tr>
<td>Average dose of radiotherapy (eGy)</td>
<td>3938±2261 [5000]</td>
</tr>
<tr>
<td>Number of dissected lymph nodes</td>
<td>18.4±4.6 [18.5]</td>
</tr>
<tr>
<td>Post-op duration (months)</td>
<td>68.2±60.9 [53.5]</td>
</tr>
<tr>
<td>Lymphedema duration (months)</td>
<td>26.3±28.8 [16.5]</td>
</tr>
<tr>
<td>Number (percentage)</td>
<td></td>
</tr>
<tr>
<td>Subjects underwent radiotherapy</td>
<td>15 (83.3%)</td>
</tr>
<tr>
<td>Subjects underwent chemotherapy</td>
<td>16 (88.9%)</td>
</tr>
<tr>
<td>Surgery type</td>
<td></td>
</tr>
<tr>
<td>Radical mastectomy</td>
<td>1 (5.6%)</td>
</tr>
<tr>
<td>Modified radical mastectomy</td>
<td>13 (72.2%)</td>
</tr>
<tr>
<td>Simple mastectomy</td>
<td>1 (5.6%)</td>
</tr>
<tr>
<td>Breast conservation</td>
<td>3 (16.7%)</td>
</tr>
<tr>
<td>Lymphedema on dominant side</td>
<td>11 (61.1%)</td>
</tr>
<tr>
<td>Previous treatment for lymphedema</td>
<td>17 (94.4%)</td>
</tr>
<tr>
<td>Pharmacologic treatment</td>
<td>3 (16.7%)</td>
</tr>
<tr>
<td>Manual lymphatic drainage</td>
<td>8 (44.4%)</td>
</tr>
<tr>
<td>Short-stretched bandage</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Elastic bandage</td>
<td>5 (27.8%)</td>
</tr>
<tr>
<td>Compression garment</td>
<td>10 (55.6%)</td>
</tr>
<tr>
<td>Remedial exercise</td>
<td>1 (5.6%)</td>
</tr>
<tr>
<td>Pneumatic compression therapy</td>
<td>17 (94.4%)</td>
</tr>
<tr>
<td>Other physical therapy modality</td>
<td>6 (33.3%)</td>
</tr>
<tr>
<td>Chinese pharmacologic treatment (herbal treatment)</td>
<td>2 (11.1%)</td>
</tr>
<tr>
<td>Chinese massage (heavy maneuver)</td>
<td>1 (5.6%)</td>
</tr>
<tr>
<td>Concurrent treatment for lymphedema</td>
<td>4 (22.2%)</td>
</tr>
</tbody>
</table>
The limb was vertically immersed in a water-filled tank until the web space between index and middle fingers touched a bar across the tank, and the displaced fluid was collected and measured by measuring cups (3000 c.c. and 5000 c.c.) and cylinders (100 c.c.) with various volume and graduated scale. The value of each scale were 50 c.c. for measuring cups and 1 c.c. for the cylinder. The measurement of water-displacement was conducted twice for each limb and the average data was used to analyze. The circumference of both arms was also measured, starting from the wrist and measured every 3 cm proximally to the axilla. We calculated the average circumference of the whole arm and specific parts of the arm by averaging the individual circumferences of the whole upper extremity, the upper half of the upper arm, the lower half of the upper arm, and the forearm. If there were n above-elbow circumference measurements, the upper n/2 measurements were used in calculation of the circumference of the upper half of the upper arm; the other n/2 circumference measurements were used for circumference of the lower half of the upper arm. If there were an odd number of above-elbow circumference measurements, the upper (n+1)/2 circumference measurements were used for the upper half of the upper arm. According to the previous studies, both the inter-rater and intra-rater reliability of water displacement measurement and circumference measurement were high (r = 0.99).\textsuperscript{23,24}

**Water composition of the upper extremity**

Water composition represents the volume percentage of water in the upper extremity. Too much water content represents the edema. Decreased excess water composition means improvement after intervention. An eight-polar tactile-electrode impedance meter (Inbody 3.0, Biospace, Seoul, Korea) was used for the water composition analysis. Resistance (R) of the arms, trunk, and legs could be measured and reported respectively. According to Bedogni’s study, the coefficients of variation calculated from repeated measurement were 1.7~2.8% for all segments and frequencies. The validity study of Inbody has been conducted using deuterium oxide dilution as the gold standard of body water measurement. There was a significant correlation between the total body water estimated by Inbody and by deuterium oxide dilution.\textsuperscript{25}

**Lymphedema-related symptoms**

Researchers have described various physiological symptoms associated with lymphedema. Williams et al. used 11 lymphedema-related symptoms to evaluate the effects of intervention.\textsuperscript{14} We revised the outcome variables from Williams’ study after discussion with seven lymphedema patients and three experienced physical therapists. The final symptoms used in this study were tightness, heaviness, pain, hardness, soreness, discomfort, heat, fullness, tingling, weakness, and numbness. These symptoms were assessed by a visual analog scale (VAS) from 0 to 10 (0 = none and 10 = worst possible). These eleven arm symptoms have good content validity.\textsuperscript{11,14,17,26,27}

**Health-related quality of life**

We used the global HRQL item in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) to represent patients’ HRQL.\textsuperscript{28} It was originally a likert scale with seven point and changed to a 0-100 score. A higher score indicates a better health status.

**Compliance**

We recorded the compliance of applying bandage and home exercise during the intervention period. The former recorded the daily length of time of bandage application, and the latter recorded the daily home exercise frequency. A calendar was given to each subject to record the hours they wore the bandage, daily frequency of self-exercise, and any other side effect (wounds developed or feeling itchy due to usage of bandage).

**Data Analysis**

Difference of measured value between the affected side and the sound side was calculated as excess limb volume, excess circumference and excess water composition. The quality of life score was calculated with the transformation formula provided by the EORTC QLQ-C30 Scoring Manual.

SPSS (Statistical Package for the Social Sciences) v11.0 was used in this study. One-way repeated measures for normal distributed data and Friedman tests for non-normal distributed data were used to compare the differences among the three evaluations. The level of statistical significance was set at 0.05. Six ANOVAs were conducted on excess water displacement, excess circumferences on upper part, lower part of upper arm
and forearm, excess water composition, and then the confidence value was set to be 0.05/6=0.0083. Considering the issue of multiple comparisons in the post hoc test of one-way repeated measures for the symptoms, we used Bonferroni correction, $\alpha$ was set at 0.0167 (0.05/3).

**RESULTS**

Eighteen subjects aged 57.9±9.8 years (ranging from 43 to 74) fulfilling the inclusion and exclusion criteria were recruited. Baseline and demographic data are shown in Table 1. Most of the subjects (72.2%) received a modified mastectomy and underwent radiotherapy and chemotherapy. The average duration between onset of lymphedema and our intervention was 26.3±28.8 months. Over 90% of subjects had received previous treatment for lymphedema.

The measurements of excess limb size and water composition are shown in Table 2. There were significant reductions of excess limb size and excess water composition after the intervention period ($p<0.0083$) except on the upper half of the upper arm. The volume reduction after the intervention period averaged 18.8%. The effect sizes of these measurements ranged from 0.35-0.56 for the statistically significant changes (small to medium effect size).

The data for the lymphedema-related symptoms are presented in Table 3. The three highest mean score symptoms at the initial evaluation were discomfort (4.40±3.80), fullness (4.37±3.79) and tightness (4.36±3.64). Most of the symptoms seemed to be worsened during the control phase but no statistically significant difference. At the end of the intervention period, five symptoms were found to be significantly reduced. These were tightness ($p=0.006$), heaviness ($p=0.003$), soreness ($p=0.005$), discomfort ($p=0.001$) and fullness ($p=0.002$).

Global HRQL score decreased from 64.4±21.0 to 61.6±22.2 during control period and increased to 64.4±21.4 after intervention period. There was no significant change among the 3 evaluations.

All subjects attended all scheduled sessions for treatment. During the intervention period, the average exercise frequency was 1.8 times per day. Duration of bandage application was 7.7±3.9 hours in the daytime and 5.8±2.0 hours in the night. Six patients felt itchy, no wound was present during the intervention period.

**DISCUSSION**

The use of DLT combined with PC in this study has shown positive therapeutic responses. There was a statistically significant reduction in the excess limb volume and circumference of the lower half of the upper arm and the forearm. Significant changes in water composition and five symptoms were also noted.

The excess circumference change of the upper half of the upper arm was not significant. Possible explanations might be insufficient clearance of the proximal part, insufficient coverage of the bandage (bandages were applied to the upper arm,
but they tended to slide down), and the impact of pneumatic compression therapy (bring the lymphatic fluid from the distal part of limb to the proximal part).

It was not significant in the change of VAS measurement of the symptoms in every item. Although patients felt good subjectively after the intervention, six symptoms (pain, hardness, heat, tingling, weakness and numbness) showed no significant change after intervention period. The reason should be studied further.

Comparing our result (reduction in volume = 18.8%) with previous studies, the volume reduction is less than others’ (19.3%~67%)\(^8,10-17\) except in William’s study (9.15%).\(^14\) There are several factors that might contribute to this finding, including the chronicity of our participants, this might make their improvement within one month being difficult, the delay in evaluation after the final treatment session, poor compliance in bandage application of subjects, previous lymphedema-related treatments and the muscle bulk in the affected limb might be larger because of exercise when intervention, this also can make the difference become smaller.

The timing of the final evaluation might be a contributing factor affecting the result. To eliminate the influence of any fluctuation of severity of the lymphedema, we arranged a fixed time point for all three evaluations (e.g., if the subject received her first evaluation at 9 a.m., her other evaluations were at 9 a.m. as well). This meant that the schedule of third evaluation might have been arranged one or two days after the final treatment session. In order to understand how the timing of the evaluation affected the results, we compared the results of five subjects who were evaluated twice – once right after the final treatment session and again, one to two days after the final treatment according to the usual schedule. Their volume reduction measured immediately after the last treatment was higher (26.9%) than that measured at our scheduled time (21.4%). This might be an evidence that the evaluation time was a factor which influenced the final measurements. It is possible that many of the other researchers measured the effectiveness of the intervention right after the treatment, whereas there was a delay of one to two days in this study. Aside from the time of evaluation, we did not control the patients’ activities before the evaluation, this may also cause the fluctuation of measured outcomes.

Although attending to the treatment was perfect, poor compliance of bandage application might also limit the treatment effect. Aside from attending the treatment, patients did home exercise less than twice per day, this might hinder their improvement. Most of the researchers did not evaluate patient compliance in using bandage. The subjects in our study used bandages according to the individual’s tolerance. The average

---

**Table 3. Lymphedema-related Symptoms among Three Measurement Periods**

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>1st measurement Mean (SD)</th>
<th>2nd measurement Mean (SD)</th>
<th>3rd measurement Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tightness</td>
<td>4.36 (3.64)</td>
<td>4.71 (3.36)</td>
<td>2.29* (2.33)</td>
</tr>
<tr>
<td>Heaviness</td>
<td>4.27 (3.38)</td>
<td>4.11 (3.22)</td>
<td>1.86* (2.07)</td>
</tr>
<tr>
<td>Pain</td>
<td>2.16 (3.28)</td>
<td>1.93 (3.41)</td>
<td>1.30 (2.29)</td>
</tr>
<tr>
<td>Hardness</td>
<td>4.30 (3.38)</td>
<td>3.69 (3.38)</td>
<td>2.27 (2.62)</td>
</tr>
<tr>
<td>Soreness</td>
<td>3.18 (3.32)</td>
<td>3.84 (3.55)</td>
<td>1.73* (2.43)</td>
</tr>
<tr>
<td>Discomfort</td>
<td>4.40 (3.80)</td>
<td>3.61 (3.42)</td>
<td>1.76* (2.35)</td>
</tr>
<tr>
<td>Heat</td>
<td>1.35 (2.58)</td>
<td>2.06 (3.06)</td>
<td>1.48 (2.43)</td>
</tr>
<tr>
<td>Fullness</td>
<td>4.37 (3.79)</td>
<td>4.58 (3.51)</td>
<td>2.17* (2.33)</td>
</tr>
<tr>
<td>Tingling</td>
<td>1.63 (2.89)</td>
<td>1.74 (3.13)</td>
<td>1.18 (2.27)</td>
</tr>
<tr>
<td>Weakness</td>
<td>3.17 (3.47)</td>
<td>2.61 (3.68)</td>
<td>1.46 (1.86)</td>
</tr>
<tr>
<td>Numbness</td>
<td>2.29 (3.74)</td>
<td>2.39 (3.66)</td>
<td>1.26 (1.87)</td>
</tr>
</tbody>
</table>

* a significant difference with previous measurement result (p<0.0167)
duration of bandage use was 7.7±3.9 hours during the day and 5.8±2.0 hours at night. The limited duration of bandage use might curtail the reduction of lymphedema. It is important to find an alternative treatment for those patients.

Lymphedema is a progressive condition, the subjects were influenced by their previous treatment. Four of our subjects even underwent concurrent treatments. These might also make our treatment effects less prominent. Most researchers did not mention any previous treatment history prior to their study except in Szuba’s and Mcneely’s study. Szuba’s study was undertaken into two phases. The first phase was designed for patients with previous untreated lymphedema, the second phase was designed for patients completed previous treatment for at least one month and less than 1 year. None of subjects in Mcneely’s study received active treatment for lymphedema within the 6 months prior to entering the study. In our study, 94.4% of the subjects received previous lymphedema-related treatment, which might cause a ceiling effect and limit the effectiveness of our treatment.

We used the subjects themselves as controls, tried to make up for the ethical limitations of the former quasi-experimental studies. Moreover, we recruited subjects who had been suffering from lymphedema for at least 3 months to assure the chronicity. However, slow progression of lymphedema in control period in most parameters was still noted. The duration of the control period might need to be lengthened in future studies.

In conclusion, although the effect was not prominent, the use of DLT combined with PC in this study has shown positive therapeutic responses.

ACKNOWLEDGEMENT

The authors thank all the participants and the National Science Council of the Republic of China for financial support under grant no. NSC93-2314-B-002-118, which made this study possible.

REFERENCES

24. 蔡涵如，劉敏，曹昭鈞。淋巴水腫評估法之信度研究。物理治療 2005：30：124-31。
減腫脹淋巴療法對乳癌相關
淋巴水腫之療效

蔡涵如1 洪秀娟1 楊靜蘭2 黃俊升3 曹昭懿1,4,*

背景與目的：有關減腫脹淋巴療法療效的研究多缺乏控制組，因此，本研究設計以接受或不接受治療者本身為對照組，以降低自然病程之影響，來檢測本療法對乳癌相關淋巴水腫之療效。方法：以罹患淋巴水腫超過 3 個月以上之單側乳癌病人為對象。收案後，每位病人皆以 1 個月為控制期，再接著 1 個月之介入期，在控制期前、後及介入期之後共接受 3 次評估。在介入期間，每位病人接受每週五次，每次 2 小時（包括 1 小時減腫脹淋巴療法及 1 小時循環機治療），共四周。評估項目包括病史及醫療資料、腫脹程度、上肢水腫、淋巴水腫及生活品質等評價。結果：控制期間各項測量均未有顯著改變；在介入後，多餘腫脹程度、上肢水腫及生活品質皆有顯著減少（p<0.0083），有五項自評有明顯改善（p<0.0167）。結論：減腫脹淋巴療法加上循環機治療對於乳癌淋巴水腫有正向之療效。（物理治療 2010;35(2):89-97）

關鍵詞：乳癌、乳癌相關淋巴水腫、減腫脹淋巴療法、淋巴水腫

1 臺灣大學醫學中心物理治療學系暨研究所
2 臺灣大學醫學中心附設醫院物理治療技術科
3 臺灣大學醫學中心附設外科
4 臺灣大學醫學中心附設物理治療中心

通訊作者：曹昭懿 臺灣大學醫學中心物理治療學系暨研究所 台北市徐州路 17 號 3 樓
電話：02-33668130 E-mail：jytasuo@ntu.edu.tw
收件日期：99年 3月 30日  修訂日期：99年 5月 4 日  接受日期：99年 5月 11 日